Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MetFORMIN 500 Mg Oral Tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02065752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/500 mg, CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
38
States / cities
Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

NCT00899470
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

NCT00643851
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 27, 2026, 6:45 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

NCT01204775
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo (Saxagliptin), Metformin IR, Placebo (Metformin), Metformin (Active Rescue)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

NCT01441869
View directory record Official record
Conditions
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions
Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

NCT06042855
View directory record Official record
Conditions
Covid19
Interventions
Placebo, Metformin
Other · Drug
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
3,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
110
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Metformin, Placebo, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Concord, California • Encinitas, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

NCT01192152
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 27, 2026, 6:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

AMPK-activation by Metformin in FSGS: AMP-FSGS

NCT06090227
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Metformin + Standard of Care, Placebo + Standard of Care
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Regulation as Endometriosis Adjunct Treatment

NCT06611501
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 27, 2026, 6:45 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

Safety and Feasibility of Metformin for Sepsis Induced AKI

NCT05900284
View directory record Official record
Conditions
Sepsis, Septic Shock, Acute Kidney Injury, Metformin
Interventions
Metformin low dose, Metformin high dose, Placebo
Drug
Lead sponsor
Hernando Gomez
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

NCT05365451
View directory record Official record
Conditions
Interaction, Endogenous Biomarkers
Interventions
MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 27, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

Exemestane-RAD001-Metformin

NCT01627067
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

NCT00859898
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Metformin XR, dapagliflozin matching Placebo, metformin HCl Modified Release matching Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
64
States / cities
Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02077803
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin

NCT02552355
View directory record Official record
Conditions
Physical Activity
Interventions
Metformin, Placebo, Carbohydrate Beverage, Protein Beverage
Drug · Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

NCT00918138
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Redlands, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 27, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Study of Metformin Therapy in ADPKD

NCT02903511
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 27, 2026, 6:45 PM EDT